Safety and efficacy of intrarenal arterial autologous CD34+ cell transfusion in patients with chronic kidney disease: A randomized, open-label, controlled phase II clinical trial.
Chih-Chao YangPei-Hsun SungBen-Chung ChengYi-Chen LiYi-Ling ChenMel S LeeHon-Kan YipPublished in: Stem cells translational medicine (2020)
CD34+ cell therapy was safe and improved 1-year outcome.